Johnson & Johnson (JNJ) Price & Analysis

Compare

27,510 Followers

JNJ Stock Chart & Stats

$210.33

-$4.08(-2.79%)

At close: Jan 08 4:00 PM EST

$210.33

-$4.08(-2.79%)

Day’s Range― - ―

52-Week Range$140.68 - $215.19

Previous CloseN/A

Volume3.80M

Average Volume (3M)8.67M

Market Cap

$504.27B

Enterprise Value$463.68B

Total Cash (Recent Filing)$18.56B

Total Debt (Recent Filing)$6.39B

Price to Earnings (P/E)20.2

Beta0.11

Next Earnings

Jan 21, 2026

EPS Estimate

2.53

Next Dividend Ex-DateN/A

Dividend Yield2.44%

Share Statistics

EPS (TTM)2.80

Shares Outstanding2,409,295,200

10 Day Avg. Volume8,488,585

30 Day Avg. Volume8,668,637

Financial Highlights & Ratios

PEG Ratio-0.42

Price to Book (P/B)4.83

Price to Sales (P/S)3.88

P/FCF Ratio17.39

Enterprise Value/Market Cap0.92

Enterprise Value/Revenue5.03

Enterprise Value/Gross Profit7.39

Enterprise Value/Ebitda11.72

Forecast

1Y Price Target

$215.35

Price Target Upside2.39% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering20

EPS Forecast (FY)10.87

Revenue Forecast (FY)$93.75B

Bulls Say, Bears Say

Bulls Say

Corporate StrategyJNJ announced a planned separation of its ortho business, which should boost the company's outer year growth.

Pharmaceutical AdvancementsTecvayli + Darzalex demonstrated significantly improved progression-free survival and overall response rates in the MajesTEC-3 trial, indicating strong efficacy in the treatment setting.

Stock PerformanceJNJ shares have continued their impressive performance, with the stock up approximately 30% since July 1.

Bears Say

Pipeline ChallengesOpportunities for further re-rate are constrained by limited pipeline catalysts and lack of conviction on upward estimate revisions.

Tax ImplicationsJNJ now expects a higher tax rate of 17.5%-18.0% due to the OBBBA.

Valuation ConcernsThe stock is rated as Neutral with about-average growth and an above-average valuation, implying JNJ is fairly valued.

Johnson & Johnson News

Johnson & Johnson price target raised to $240 from $213 at Goldman Sachs

Goldman Sachs analyst Asad Haider raised the firm’s price target on Johnson & Johnson to $240 from $213...

22m ago

JNJ

Johnson and Johnson’s Rybrevant Faspro combination in NSCLC approved by FDA

Johnson & Johnson (JNJ) has received approval from the FDA for Rybrevant Faspro – amivantamab and hyaluronidase-lpuj -,...

36m ago

JNJ

HALO

Johnson & Johnson announces FDA approved Rybrevant in NSCLC patients

Johnson & Johnson “announced that the FDA approved RYBREVANT FASPRO, amivantamab and hyaluronidase-lpuj, the first and only subcutaneously...

13h ago

JNJ

3 Best ETFs to Invest In, According to AI Analyst, 12/17/2025

With thousands of ETFs to choose from, finding the right place to start isn’t easy. TipRanks’ ETF AI...

20h ago

IYH

JNJ

Johnson & Johnson price target raised to $240 from $230 at RBC Capital

RBC Capital raised the firm’s price target on Johnson & Johnson to $240 from $230 and keeps an...

23h ago

JNJ

Johnson & Johnson Rival Medline Pulls Off $6B IPO, Topping 2025 Deal Table

Medical supply firm Medline Industries, a rival to pharma giant Johnson & Johnson ($JNJ), on Tuesday raised $6.3...

1d ago

3 Best ETFs to Invest In, According to AI Analyst, 12/15/2025

A crowded landscape of exchange-traded funds (ETFs) can make it hard to know where to start. However, TipRanks’...

3d ago

JNJ

MCK

Johnson & Johnson price target raised to $220 from $204 at BofA

BofA raised the firm’s price target on Johnson & Johnson to $220 from $204 and keeps a Neutral...

3d ago

JNJ

Johnson & Johnson announces FDA approved sNDA for AKEEGA plus prednisone

Johnson & Johnson announced the U.S. Food and Drug Administration, FDA, approved the supplemental New Drug Application, sNDA,...

4d ago

JNJ

FDA approves J&J’s Akeega BRCA2-mutated prostate cancer

The Food and Drug Administration said it approved Akeega with prednisone for adults with deleterious or suspected deleterious...

6d ago

JNJ

Johnson & Johnson price target raised to $197 from $190 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Johnson & Johnson to $197 from $190 and keeps an...

6d ago

JNJ

Johnson & Johnson price target raised to $230 from $209 at RBC Capital

RBC Capital raised the firm’s price target on Johnson & Johnson to $230 from $209 and keeps an...

7d ago

JNJ

Johnson & Johnson price target raised to $232 from $215 at Citi

Citi analyst Joanne Wuensch raised the firm’s price target on Johnson & Johnson to $232 from $215 and...

7d ago

JNJ

LLY, PFE: Eli Lilly’s Mounjaro, Pfizer’s Cancer Drug Added to China’s State Insurance List

Eli Lilly’s ($LLY) Mounjaro and Pfizer’s ($PFE) cancer drugs were added to China’s state-run health insurance scheme, according...

10d ago

JNJ

LLY

JNJ FAQ

What was Johnson & Johnson’s price range in the past 12 months?

Johnson & Johnson lowest stock price was $140.68 and its highest was $215.19 in the past 12 months.

What is Johnson & Johnson’s market cap?

Johnson & Johnson’s market cap is $504.27B.

When is Johnson & Johnson’s upcoming earnings report date?

Johnson & Johnson’s upcoming earnings report date is Jan 21, 2026 which is in 34 days.

How were Johnson & Johnson’s earnings last quarter?

Johnson & Johnson released its earnings results on Oct 14, 2025. The company reported $2.8 earnings per share for the quarter, beating the consensus estimate of $2.757 by $0.043.

Is Johnson & Johnson overvalued?

According to Wall Street analysts Johnson & Johnson’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Johnson & Johnson pay dividends?

Johnson & Johnson pays a Quarterly dividend of $1.3 which represents an annual dividend yield of 2.44%. See more information on Johnson & Johnson dividends here

What is Johnson & Johnson’s EPS estimate?

Johnson & Johnson’s EPS estimate is 2.53.

How many shares outstanding does Johnson & Johnson have?

Johnson & Johnson has 2,409,295,200 shares outstanding.

What happened to Johnson & Johnson’s price movement after its last earnings report?

Johnson & Johnson reported an EPS of $2.8 in its last earnings report, beating expectations of $2.757. Following the earnings report the stock price went down -0.032%.

Which hedge fund is a major shareholder of Johnson & Johnson?

Currently, no hedge funds are holding shares in JNJ

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Johnson & Johnson Stock Smart Score

Outperform

Fundamentals

Return on Equity

33.62%

Trailing 12-Months

Asset Growth

8.15%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Johnson & Johnson

Johnson & Johnson (JNJ) is a multinational corporation headquartered in New Brunswick, New Jersey, specializing in the development, manufacturing, and marketing of a diverse range of healthcare products. The company operates in three main sectors: Pharmaceuticals, Medical Devices, and Consumer Health. Its core products include prescription medications, surgical devices, over-the-counter consumer health products, and personal care items, such as baby care, skin and wound care, and over-the-counter pharmaceuticals. With a commitment to innovation and a strong portfolio of brands, Johnson & Johnson serves customers in more than 175 countries worldwide.

Johnson & Johnson (JNJ) Earnings & Revenues

Historic Earnings Reports

JNJ Company Deck

JNJ Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

Johnson & Johnson demonstrated strong overall performance with significant growth across key segments and successful new product launches. Despite challenges from STELARA's loss of exclusivity and increased tax rates, the company's strategic focus and operational achievements suggest a positive outlook.View all JNJ earnings summaries

JNJ Sales Breakdown

64.13% Innovative Medicine

35.87% MedTech

JNJ Stock 12 Month Forecast

Average Price Target

$215.35

▲(2.39% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"139":"$139","190":"$190","241":"$241","164.5":"$164.5","215.5":"$215.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":240,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$240.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":215.35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$215.35</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":190,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$190.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[139,164.5,190,215.5,241],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,205.34,208.00615384615384,210.6723076923077,213.33846153846153,216.0046153846154,218.67076923076922,221.33692307692309,224.00307692307692,226.66923076923078,229.3353846153846,232.00153846153847,234.6676923076923,237.33384615384617,{"y":240,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,205.34,206.11,206.88,207.65,208.42,209.19,209.96,210.73,211.5,212.27,213.04,213.81,214.57999999999998,{"y":215.35,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,205.34,204.16,202.98,201.8,200.62,199.44,198.26,197.08,195.9,194.72,193.54,192.36,191.18,{"y":190,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":150.2,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":140.32,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":147.63,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":161.4,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":149.89,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":151.07,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":153.29,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":153.81,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":165.06,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":176.94,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":184.88,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":187.68,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":205.34,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >